Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director · Bd. Co-Chair, President & CEO | December 31, 2025 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 31, 2025 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 214,523 |
Ending reported balance
After 2025-12-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-12-31 · Exercise / conversion · Acquired 28,570 · Balance 243,093 Row 2 · 2025-12-31 · Tax withholding · Disposed 28,570 · Balance 214,523 |
| 2020 Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 595,077 |
Reported balance
After 2025-12-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-12-31 · Exercise / conversion · Disposed 28,570 · Balance 595,077 F1: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company. |
| Common StockSEC Table I · non-derivative | IndirectBy 2024 GRAT | 127,484 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 127,484 |
| Common StockSEC Table I · non-derivative | IndirectBy 2025 GRAT | 300,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 300,000 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 5,989 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 5,989 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 39,985 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 39,985 |
Filing footnotes · ownership attribution and instrument terms
F1: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2025 Filed Jan 5, 2026 22:53 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversion2020 Performance Stock Units · Derivative | 28,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001218629-26-000002 · edgardoc.xml · derivative · entry 7 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 595,077 Underlying: Common Stock · 28,570 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company. F1 · derivative.exercise_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company. F1 · derivative.expiration_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:53 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 28,570 | $772.09 | $22,058,611.30 |
DisclosureSEC source: 0001218629-26-000002 · edgardoc.xml · nonDerivative · entry 2 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,523 Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:53 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 28,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001218629-26-000002 · edgardoc.xml · nonDerivative · entry 1 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,093 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 172,723 | $0.00 Strike: $555.67 | $0.00 |
DisclosureSEC source: 0001218629-25-000006 · edgardoc.xml · derivative · entry 7 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 172,723 shares Expires 2025-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 155,145 | $701.51 | $108,835,768.95 |
DisclosureSEC source: 0001218629-25-000006 · edgardoc.xml · nonDerivative · entry 2 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,523 Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 172,723 | $555.67 | $95,976,989.41 |
DisclosureSEC source: 0001218629-25-000006 · edgardoc.xml · nonDerivative · entry 1 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 369,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | ConversionClass A Stock · Derivative | 1,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-071247 · tm2417175-1_4seq1.xml · derivative · entry 10 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust for Son Disclosed balance after: 14,775 Underlying: Common Stock · 1,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Class A Stock of the Company converts to common stock of the Company on a one-to-one basis upon certain events or upon election of the shareholder. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. F8 · derivative.exercise_date: These shares of Class A Stock are presently convertible and such conversion feature does not expire. F8 · derivative.expiration_date: These shares of Class A Stock are presently convertible and such conversion feature does not expire. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $1,025.27 | $1,025,270.00 |
DisclosureSEC source: 0001104659-24-071247 · tm2417175-1_4seq1.xml · nonDerivative · entry 9 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust for Son Disclosed balance after: 0 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. F6 · price: Represents volume-weighted average price of sales of 1,000 shares of Company stock on June 12, 2024 at prices ranging from $1,025.00 to $1,025.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2024 at each separate price. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | ConversionCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-071247 · tm2417175-1_4seq1.xml · nonDerivative · entry 8 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust for Son Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 270 | $1,016.62 | $274,487.40 |
DisclosureSEC source: 0001104659-24-071247 · tm2417175-1_4seq1.xml · nonDerivative · entry 6 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 39,985 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. F5 · price: Represents volume-weighted average price of sales of 270 shares of Company stock on June 12, 2024 at prices ranging from $1,016.10 to $1,016.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2024 at each separate price. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 14,879 | $1,015.30 | $15,106,648.70 |
DisclosureSEC source: 0001104659-24-071247 · tm2417175-1_4seq1.xml · nonDerivative · entry 5 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 40,255 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. F4 · price: Represents volume-weighted average price of sales of 14,879 shares of Company stock on June 12, 2024 at prices ranging from $1,015.00 to $1,015.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2024 at each separate price. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,743 | $1,016.04 | $1,770,957.72 |
DisclosureSEC source: 0001104659-24-071247 · tm2417175-1_4seq1.xml · nonDerivative · entry 4 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 55,134 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. F3 · price: Represents volume-weighted average price of sales of 1,743 shares of Company stock on June 11, 2024 at prices ranging from $1,016.04 to $1,016.10. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 11, 2024 at each separate price. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7,321 | $1,015.28 | $7,432,864.88 |
DisclosureSEC source: 0001104659-24-071247 · tm2417175-1_4seq1.xml · nonDerivative · entry 3 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 56,877 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. F2 · price: Represents volume-weighted average price of sales of 7,321 shares of common stock of Regeneron Pharmaceuticals, Inc. (the "Company") on June 11, 2024 at prices ranging from $1,015.00 to $1,015.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 11, 2024 at each separate price. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 787 | $1,015.02 | $798,820.74 |
DisclosureSEC source: 0001883850-24-000029 · edgardoc.xml · nonDerivative · entry 1 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 64,198 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. F2 · price: Represents volume-weighted average price of sales of 787 shares of Company stock on June 6, 2024 at prices ranging from $1,015.00 to $1,015.25. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 6, 2024 at each separate price. Read SEC document |
| May 17, 2024 Filed May 17, 2024 21:57 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 143 | $980.07 | $140,150.01 |
DisclosureSEC source: 0001883850-24-000025 · edgardoc.xml · nonDerivative · entry 2 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,877 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. F3 · price: Represents volume-weighted average price of sales of 143 shares of Company stock on May 17, 2024 at prices ranging from $980.01 to $980.20. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2024 at each separate price. Read SEC document |
| May 17, 2024 Filed May 17, 2024 21:57 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 22,687 | $979.22 | $22,215,564.14 |
DisclosureSEC source: 0001883850-24-000025 · edgardoc.xml · nonDerivative · entry 1 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 467,020 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. F2 · price: Represents volume-weighted average price of sales of 22,687 shares of Company stock on May 17, 2024 at prices ranging from $979.00 to $979.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 15, 2024 22:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 299 | $988.76 | $295,639.24 |
DisclosureSEC source: 0001883850-24-000022 · edgardoc.xml · nonDerivative · entry 14 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 397,259 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. F13 · price: Represents volume-weighted average price of sales of 299 shares of Company stock on May 15, 2024 at prices ranging from $988.00 to $988.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 15, 2024 22:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 228 | $987.46 | $225,140.88 |
DisclosureSEC source: 0001883850-24-000022 · edgardoc.xml · nonDerivative · entry 13 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 397,558 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. F12 · price: Represents volume-weighted average price of sales of 228 shares of Company stock on May 15, 2024 at prices ranging from $987.31 to $987.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 15, 2024 22:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 103 | $986.57 | $101,616.71 |
DisclosureSEC source: 0001883850-24-000022 · edgardoc.xml · nonDerivative · entry 12 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 397,786 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. F11 · price: Represents volume-weighted average price of sales of 103 shares of Company stock on May 15, 2024 at prices ranging from $986.37 to $986.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 15, 2024 22:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 281 | $985.72 | $276,987.32 |
DisclosureSEC source: 0001883850-24-000022 · edgardoc.xml · nonDerivative · entry 11 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 397,889 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. F10 · price: Represents volume-weighted average price of sales of 281 shares of Company stock on May 15, 2024 at prices ranging from $985.13 to $985.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 15, 2024 22:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 305 | $984.00 | $300,120.00 |
DisclosureSEC source: 0001883850-24-000022 · edgardoc.xml · nonDerivative · entry 10 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 398,170 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. F9 · price: Represents volume-weighted average price of sales of 305 shares of Company stock on May 15, 2024 at prices ranging from $984.00 to $984.02. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 15, 2024 22:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 250 | $983.91 | $245,977.50 |
DisclosureSEC source: 0001883850-24-000022 · edgardoc.xml · nonDerivative · entry 9 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 398,475 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. F8 · price: Represents volume-weighted average price of sales of 250 shares of Company stock on May 15, 2024 at prices ranging from $983.82 to $983.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 15, 2024 22:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 235 | $982.66 | $230,925.10 |
DisclosureSEC source: 0001883850-24-000022 · edgardoc.xml · nonDerivative · entry 8 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 398,725 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. F7 · price: Represents volume-weighted average price of sales of 235 shares of Company stock on May 15, 2024 at prices ranging from $982.31 to $982.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 15, 2024 22:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,081 | $981.50 | $1,061,001.50 |
DisclosureSEC source: 0001883850-24-000022 · edgardoc.xml · nonDerivative · entry 7 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 398,960 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. F6 · price: Represents volume-weighted average price of sales of 1,081 shares of Company stock on May 15, 2024 at prices ranging from $981.09 to $981.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 15, 2024 22:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 295 | $980.64 | $289,288.80 |
DisclosureSEC source: 0001883850-24-000022 · edgardoc.xml · nonDerivative · entry 6 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 400,041 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. F5 · price: Represents volume-weighted average price of sales of 295 shares of Company stock on May 15, 2024 at prices ranging from $980.17 to $980.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 15, 2024 Filed May 15, 2024 22:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7,864 | $979.05 | $7,699,249.20 |
DisclosureSEC source: 0001883850-24-000022 · edgardoc.xml · nonDerivative · entry 5 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 400,336 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. F4 · price: Represents volume-weighted average price of sales of 7,864 shares of Company stock on May 15, 2024 at prices ranging from $979.00 to $979.50. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 15, 2024 at each separate price. Read SEC document |
| May 14, 2024 Filed May 15, 2024 22:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,302 | $980.10 | $2,256,190.20 |
DisclosureSEC source: 0001883850-24-000022 · edgardoc.xml · nonDerivative · entry 4 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 408,200 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. F3 · price: Represents volume-weighted average price of sales of 2,302 shares of Company stock on May 14, 2024 at prices ranging from $980.00 to $980.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 14, 2024 at each separate price. Read SEC document |
| May 14, 2024 Filed May 15, 2024 22:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 22,698 | $979.16 | $22,224,973.68 |
DisclosureSEC source: 0001883850-24-000022 · edgardoc.xml · nonDerivative · entry 3 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 410,502 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. F2 · price: Represents volume-weighted average price of sales of 22,698 shares of Company stock on May 14, 2024 at prices ranging from $979.00 to $979.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 14, 2024 at each separate price. Read SEC document |
| May 13, 2024 Filed May 15, 2024 22:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 203,204 | $0.00 Strike: $399.66 | $0.00 |
DisclosureSEC source: 0001883850-24-000022 · edgardoc.xml · derivative · entry 18 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 203,204 shares Expires 2024-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. F14 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| May 13, 2024 Filed May 15, 2024 22:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 144,433 | $976.79 | $141,080,710.07 |
DisclosureSEC source: 0001883850-24-000022 · edgardoc.xml · nonDerivative · entry 2 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 433,200 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. Read SEC document |
| May 13, 2024 Filed May 15, 2024 22:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 203,204 | $399.66 | $81,212,510.64 |
DisclosureSEC source: 0001883850-24-000022 · edgardoc.xml · nonDerivative · entry 1 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 577,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversion2019 Performance Stock Units · Derivative | 25,155 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001883850-23-000094 · edgardoc.xml · derivative · entry 6 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,155 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On December 11, 2019, the reporting person was granted performance-based restricted stock units ("PSUs") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return ("TSR") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended. F1 · price: On December 11, 2019, the reporting person was granted performance-based restricted stock units ("PSUs") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return ("TSR") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended. F1 · derivative.exercise_date: On December 11, 2019, the reporting person was granted performance-based restricted stock units ("PSUs") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return ("TSR") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended. F1 · derivative.expiration_date: On December 11, 2019, the reporting person was granted performance-based restricted stock units ("PSUs") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return ("TSR") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 12,841 | $844.09 | $10,838,959.69 |
DisclosureSEC source: 0001883850-23-000094 · edgardoc.xml · nonDerivative · entry 2 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374,429 Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 25,155 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001883850-23-000094 · edgardoc.xml · nonDerivative · entry 1 SCHLEIFER LEONARD S · CIK 0001218629 · Director · Bd. Co-Chair, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 387,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On December 11, 2019, the reporting person was granted performance-based restricted stock units ("PSUs") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return ("TSR") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 53,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-23-000069 · edgardoc.xml · nonDerivative · entry 2 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 64,985 Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 53,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-23-000069 · edgardoc.xml · nonDerivative · entry 1 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · 2021 GRAT Disclosed balance after: 0 Read SEC document |
| April 06, 2022 Filed Apr 7, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,653 | $710.04 | $1,883,736.12 |
DisclosureSEC source: 0001883850-22-000038 · edgardoc.xml · nonDerivative · entry 2 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 11,178 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 2,653 shares of Company stock on April 6, 2022 at prices ranging from $710.00 to $710.13. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 6, 2022 at each separate price. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,461 | $710.05 | $3,167,533.05 |
DisclosureSEC source: 0001883850-22-000038 · edgardoc.xml · nonDerivative · entry 1 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 13,831 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 4,461 shares of Company stock on April 5, 2022 at prices ranging from $710.00 to $710.22. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 5, 2022 at each separate price. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,886 | $710.01 | $2,049,088.86 |
DisclosureSEC source: 0001883850-22-000036 · edgardoc.xml · nonDerivative · entry 1 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 18,292 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 2,886 shares of Company stock on March 31, 2022 at prices ranging from $710.00 to $710.10. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 31, 2022 at each separate price. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 22:50 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 239,063 | $0.00 Strike: $270.43 | $0.00 |
DisclosureSEC source: 0001883850-21-000009 · edgardoc.xml · derivative · entry 9 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 239,063 shares Expires 2023-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 22:50 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 281,250 | $0.00 Strike: $179.13 | $0.00 |
DisclosureSEC source: 0001883850-21-000009 · edgardoc.xml · derivative · entry 8 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 281,250 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 22:50 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 185,646 | $651.96 | $121,033,766.16 |
DisclosureSEC source: 0001883850-21-000009 · edgardoc.xml · nonDerivative · entry 4 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 465,922 Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 22:50 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 281,250 | $179.13 | $50,380,312.50 |
DisclosureSEC source: 0001883850-21-000009 · edgardoc.xml · nonDerivative · entry 3 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 22:50 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 173,491 | $651.96 | $113,109,192.36 |
DisclosureSEC source: 0001883850-21-000009 · edgardoc.xml · nonDerivative · entry 2 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,318 Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 22:50 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 239,063 | $270.43 | $64,649,807.09 |
DisclosureSEC source: 0001883850-21-000009 · edgardoc.xml · nonDerivative · entry 1 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 543,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10,000 | $660.03 | $6,600,300.00 |
DisclosureSEC source: 0001708138-21-000064 · edgardoc.xml · nonDerivative · entry 2 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 21,178 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 10,000 shares of Company stock on August 19, 2021 at prices ranging from $660.00 to $660.13. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 19, 2021 at each separate price. F4 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200,000 | $650.03 | $130,006,000.00 |
DisclosureSEC source: 0001708138-21-000064 · edgardoc.xml · nonDerivative · entry 1 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,746 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 200,000 shares of Company stock on August 18, 2021 at prices ranging from $650.00 to $650.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 18, 2021 at each separate price. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 303 | $629.54 | $190,750.62 |
DisclosureSEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 15 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 31,178 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F17 · price: Represents volume-weighted average price of sales of 303 shares of Company stock on August 16, 2021 at prices ranging from $629.18 to $629.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 675 | $628.41 | $424,176.75 |
DisclosureSEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 14 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 31,481 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F16 · price: Represents volume-weighted average price of sales of 675 shares of Company stock on August 16, 2021 at prices ranging from $628.03 to $628.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,111 | $627.51 | $697,163.61 |
DisclosureSEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 13 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 32,156 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · price: Represents volume-weighted average price of sales of 1,111 shares of Company stock on August 16, 2021 at prices ranging from $627.02 to $627.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.